跳转至内容
Merck
CN

MAB10009

Anti-IDO Antibody, clone 1F8.2

clone 1F8.2, from mouse

别名:

Indoleamine-pyrrole 2,3-dioxygenase, indole 2,3-dioxygenase, indoleamine 2,3-dioxygenase 1, indoleamine-pyrrole 2,3 dioxygenase, IDO1

登录 查看公司和协议定价

选择尺寸


关于此项目

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

mouse

质量水平

偶联物

unconjugated

抗体形式

purified antibody

抗体产品类型

primary antibodies

克隆

1F8.2, monoclonal

种属反应性

human

技术

immunohistochemistry: suitable
western blot: suitable

同位素/亚型

IgG1κ

NCBI登记号

UniProt登记号

运输

wet ice

靶向翻译后修饰

unmodified

基因信息

human ... IDO1(3620)

一般描述

Approx. 45 kDa
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the
suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.

免疫原

GST-tagged recombinant protein of full-length human IDO.

应用

Anti-IDO Antibody, clone 1F8.2 is an antibody against IDO for use in WB, IH.
Research Category
Neuroscience
Research Sub Category
Oxidative Stress

生化/生理作用

This antibody recognizes IDO.

外形

Protein G Purified
Format: Purified
Mouse monoclonal in buffer containing 0.1 M Tris-glycine, pH 7.4, 150 mM NaCl and 0.05% sodium azide.

制备说明

Maintain refrigerated at 2-8°C for 1 year from date of receipt.

分析说明

Control
HeLa cell lysate treated with interferon gamma.
Evaluated by Western Blot in HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL dilution of this antibody detected IDO on 15 µg of HeLa cell lysate.

其他说明

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

12 - Non Combustible Liquids

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sangjune Laurence Lee et al.
Clinical and translational radiation oncology, 17, 32-39 (2019-06-14)
Oral tongue squamous cell carcinoma (OTSCC) displays variable levels of immune cells within the tumor microenvironment. The quantity and localization of tumor infiltrating lymphocytes (TILs), specific functional TIL subsets (e.g., CD8+), and biomarker-expressing cells (e.g., PD-L1+) may have prognostic and
A Marijne Heeren et al.
Frontiers in immunology, 9, 1598-1598 (2018-07-28)
The indoleamine 2,3-dioxygenase (IDO) enzyme can act as an immunoregulator by inhibiting T cell function via the degradation of the essential amino acid tryptophan (trp) into kynurenine (kyn) and its derivates. The kyn/trp ratio in serum is a prognostic factor
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome.
Gorris, et al.
Journal for Immunotherapy of Cancer, 10 (2022)
Maria A Papadaki et al.
Cancers, 12(6) (2020-06-18)
The current study aimed at the optimization of circulating tumor cell (CTC) enrichment for downstream protein expression analyses in non-small cell lung cancer (NSCLC) to serve as a tool for the investigation of immune checkpoints in real time. Different enrichment
Trine Zeeberg Iversen et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(1), 221-232 (2013-11-13)
To investigate targeting of indoleamine 2,3 dioxygenase (IDO) enzyme using a synthetic peptide vaccine administered to patients with metastatic non-small cell lung cancer (NSCLC). In a clinical phase I study, we treated 15 HLA-A2-positive patients with stage III-IV NSCLC in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持